Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories

BMJ

Volumn 336, Issue 7653, 2008, Pages 1114-1117

  Vrijens, Bernard ^a,b   Vincze, Gäbor ^c   Kristanto, Paulus ^a   Urquhart, John ^d   Burnier, Michel ^e  

^a Pharmionic Research Center   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL STUDY; DATA BASE; ELECTRONICS; ERROR; HISTORY; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MONITORING; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PATIENT COMPLIANCE;

EID: 44349111871     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39553.670231.25     Document Type: Article

References (20)

1. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Int Med 1997;157:2413-56.
2. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive treatment. Clin Exp Hypertens 1999;21:973-85.
3. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6.
4. Hyre AD, Krousel-Wood MA, Muntner P, Kawasaki L, DeSalvo KB. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens 2007;9:179-86.
5. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure - lowering medication in ambulatory care? Arch Intern Med 2004;164:722-32.
6. Pullar T, Kumar S, Feely M. Compliance in clinical trials. Ann Rheum Dis 1989;48:871-5.
7. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. J Clin Pharmacol Ther 1990;48:676-85.
8. Caro JJ, Speckmann JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6.
9. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006;47:1039-48.
10. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990;150:1377-8.
11. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-10.
12. Duesing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001;3:488-92.
13. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007;57:81-3.
14. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005;45:461-7.
15. Urquhart J, Vrijens B. New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hospital Pharm Sci 2005;11:103-6.
16. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992;22:238-46.
17. Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetics analysis? J Pharmacokinet Biopharm 1996;24:265-82.
18. Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Meth Med Res 1999;8:247-62.
19. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 2004;42:409-22.
20. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis 1999;187:53-5.